Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $13 on Rockwell Medical Technologies on Weak EPS

Share:
Related RMTI
Rockwell Medical Q4 Losses Wider Than Expected
Brean Predicts 'A Skid And A Crash' For Rockwell Medical's Triferic Drug

Stifel Nicolaus reduced its price target on Rockwell Medical Technologies (NASDAQ: RMTI) from $15 to $13 while reiterating its Buy rating.

Stifel Nicolaus said, “Rockwell reported in-line 3Q12 revenues of $12.7mn (Consensus $12.7mn), growing 6% y/y and translating to net loss per share of $0.86 (Consensus of a $0.50 loss). Net loss was attributed to higher R&D ($16.2mn), which peaked during 3Q due to faster enrollment in the long-term SFP safety study. … Rockwell ended 3Q12 with $11.3mn in cash, and management expects business operations, excluding R&D, to be cash flow positive and build momentum into 2013. Additional sources of cash are expected from business development activities, like licensing of SFP internationally or potential partnerships. We look to 1Q13 as a transformative quarter for Rockwell's emergence as a key player in the dialysis market."

Rockwell Medical Technologies closed at $6.64 on Thursday.

Latest Ratings for RMTI

DateFirmActionFromTo
Jan 2015OppenheimerInitiates Coverage onOutperform
Nov 2014Chardan CapitalMaintainsBuy
Aug 2014FBR CapitalInitiates Coverage onUnderperform

View More Analyst Ratings for RMTI
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RMTI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→